Abstract

Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8% - 2016: 29.8%), as well as CTX-based ones (2011: 17.1% - 2016: 25.6%), whereas CAPE-based and MTX-based regimens remained stable. In the 1st-line setting, the highest ORR and DCR were observed for VRL-based regimens (single agent: 44% and 88%; combination: 36.7% and 82.4%, respectively). Assuming VRL-single agent as the referee treatment (median PFS: 7.2 months, 95% CI: 5.3–10.3), the longest median PFS were observed in VRL-combination regimens (9.5, 95%CI 88.8–11.3, HR = 0.72) and in CAPE-single agent (10.7, 95%CI 8.3–15.8, HR = 0.70). The VICTOR-6 study provides new data coming from the real-life setting, by adding new information regarding the use of mCHT as an option of treatment for MBC patients.

Original languageEnglish
Pages (from-to)7-16
Number of pages10
JournalBreast
Volume48
DOIs
Publication statusPublished - Dec 2019

Fingerprint

Breast Neoplasms
Drug Therapy
Pharmaceutical Preparations
Observation
Safety
Therapeutics

Keywords

  • Breast cancer
  • Cyclophosphamide
  • Methotrexate
  • Metronomic chemotherapy
  • Vinorelbine

ASJC Scopus subject areas

  • Surgery

Cite this

Metronomic chemotherapy for advanced breast cancer patients in the real world practice : Final results of the VICTOR-6 study. / VICTOR Study Group.

In: Breast, Vol. 48, 12.2019, p. 7-16.

Research output: Contribution to journalArticle

@article{05dbd92d60474236be775b2493dffee0,
title = "Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study",
abstract = "Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8{\%} - 2016: 29.8{\%}), as well as CTX-based ones (2011: 17.1{\%} - 2016: 25.6{\%}), whereas CAPE-based and MTX-based regimens remained stable. In the 1st-line setting, the highest ORR and DCR were observed for VRL-based regimens (single agent: 44{\%} and 88{\%}; combination: 36.7{\%} and 82.4{\%}, respectively). Assuming VRL-single agent as the referee treatment (median PFS: 7.2 months, 95{\%} CI: 5.3–10.3), the longest median PFS were observed in VRL-combination regimens (9.5, 95{\%}CI 88.8–11.3, HR = 0.72) and in CAPE-single agent (10.7, 95{\%}CI 8.3–15.8, HR = 0.70). The VICTOR-6 study provides new data coming from the real-life setting, by adding new information regarding the use of mCHT as an option of treatment for MBC patients.",
keywords = "Breast cancer, Cyclophosphamide, Methotrexate, Metronomic chemotherapy, Vinorelbine",
author = "{VICTOR Study Group} and Cazzaniga, {M. E.} and G. Pinotti and E. Montagna and D. Amoroso and R. Berardi and A. Butera and K. Cagossi and L. Cavanna and M. Ciccarese and S. Cinieri and E. Cretella and {De Conciliis}, E. and A. Febbraro and F. Ferra{\`u} and A. Ferzi and G. Fiorentini and A. Fontana and Gambaro, {A. R.} and O. Garrone and V. Gebbia and D. Generali and L. Gianni and F. Giovanardi and A. Grassadonia and V. Leonardi and P. Marchetti and E. Melegari and A. Musolino and M. Nicolini and C. Putzu and F. Riccardi and D. Santini and S. Saracchini and Sarobba, {M. G.} and Schintu, {M. G.} and G. Scognamiglio and P. Spadaro and C. Taverniti and D. Toniolo and P. Vici and V. Torri and F. Riva and M. Mazza and F. Cappuccio and {De Angelis}, C. and S. Donati and L. Orlando and L. Pizzuti and A. Rocca and D. Sarti",
year = "2019",
month = "12",
doi = "10.1016/j.breast.2019.07.006",
language = "English",
volume = "48",
pages = "7--16",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Metronomic chemotherapy for advanced breast cancer patients in the real world practice

T2 - Final results of the VICTOR-6 study

AU - VICTOR Study Group

AU - Cazzaniga, M. E.

AU - Pinotti, G.

AU - Montagna, E.

AU - Amoroso, D.

AU - Berardi, R.

AU - Butera, A.

AU - Cagossi, K.

AU - Cavanna, L.

AU - Ciccarese, M.

AU - Cinieri, S.

AU - Cretella, E.

AU - De Conciliis, E.

AU - Febbraro, A.

AU - Ferraù, F.

AU - Ferzi, A.

AU - Fiorentini, G.

AU - Fontana, A.

AU - Gambaro, A. R.

AU - Garrone, O.

AU - Gebbia, V.

AU - Generali, D.

AU - Gianni, L.

AU - Giovanardi, F.

AU - Grassadonia, A.

AU - Leonardi, V.

AU - Marchetti, P.

AU - Melegari, E.

AU - Musolino, A.

AU - Nicolini, M.

AU - Putzu, C.

AU - Riccardi, F.

AU - Santini, D.

AU - Saracchini, S.

AU - Sarobba, M. G.

AU - Schintu, M. G.

AU - Scognamiglio, G.

AU - Spadaro, P.

AU - Taverniti, C.

AU - Toniolo, D.

AU - Vici, P.

AU - Torri, V.

AU - Riva, F.

AU - Mazza, M.

AU - Cappuccio, F.

AU - De Angelis, C.

AU - Donati, S.

AU - Orlando, L.

AU - Pizzuti, L.

AU - Rocca, A.

AU - Sarti, D.

PY - 2019/12

Y1 - 2019/12

N2 - Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8% - 2016: 29.8%), as well as CTX-based ones (2011: 17.1% - 2016: 25.6%), whereas CAPE-based and MTX-based regimens remained stable. In the 1st-line setting, the highest ORR and DCR were observed for VRL-based regimens (single agent: 44% and 88%; combination: 36.7% and 82.4%, respectively). Assuming VRL-single agent as the referee treatment (median PFS: 7.2 months, 95% CI: 5.3–10.3), the longest median PFS were observed in VRL-combination regimens (9.5, 95%CI 88.8–11.3, HR = 0.72) and in CAPE-single agent (10.7, 95%CI 8.3–15.8, HR = 0.70). The VICTOR-6 study provides new data coming from the real-life setting, by adding new information regarding the use of mCHT as an option of treatment for MBC patients.

AB - Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8% - 2016: 29.8%), as well as CTX-based ones (2011: 17.1% - 2016: 25.6%), whereas CAPE-based and MTX-based regimens remained stable. In the 1st-line setting, the highest ORR and DCR were observed for VRL-based regimens (single agent: 44% and 88%; combination: 36.7% and 82.4%, respectively). Assuming VRL-single agent as the referee treatment (median PFS: 7.2 months, 95% CI: 5.3–10.3), the longest median PFS were observed in VRL-combination regimens (9.5, 95%CI 88.8–11.3, HR = 0.72) and in CAPE-single agent (10.7, 95%CI 8.3–15.8, HR = 0.70). The VICTOR-6 study provides new data coming from the real-life setting, by adding new information regarding the use of mCHT as an option of treatment for MBC patients.

KW - Breast cancer

KW - Cyclophosphamide

KW - Methotrexate

KW - Metronomic chemotherapy

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=85071249932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071249932&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2019.07.006

DO - 10.1016/j.breast.2019.07.006

M3 - Article

C2 - 31470257

AN - SCOPUS:85071249932

VL - 48

SP - 7

EP - 16

JO - Breast

JF - Breast

SN - 0960-9776

ER -